Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Imeroprubart · IMVT-1402

Monoclonal antibody · Antagonist of neonatal Fc receptor (FCGRT) · developed by Immunovant Sciences GmbH

Phase 3 Most advanced trial
IMVT Developer
2 Registered trials

What is Imeroprubart?

Imeroprubart is a human monoclonal antibody that binds the neonatal Fc receptor (FcRn) at the IgG binding site, preventing FcRn from interacting with serum IgG. This blocks FcRn-mediated IgG rescue, leading to IgG degradation. It is being studied in chronic inflammatory demyelinating polyneuropathy and generalized myasthenia gravis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
IMVT-1402
Drug type
Monoclonal antibody
Targets
neonatal Fc receptor (FCGRT)
Mechanism
Antagonist of neonatal Fc receptor (FCGRT)
Pathways
FcRn-mediated IgG recycling, IgG degradation
Therapy area
Neurology
Developer
Immunovant Sciences GmbH (IMVT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
PBD3BZ3HW6

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07039916 Phase 3 Generalized Myasthenia Gravis Recruiting IMVT
NCT07032662 Phase 2 Chronic Inflammatory Demyelinating Polyneuropathy Recruiting IMVT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Inflammatory Demyelinating PolyneuropathyGeneralized Myasthenia Gravis

Other drugs acting on FCGRT

More from Immunovant Sciences GmbH

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the IMVT page.

Follow IMVT, the company behind Imeroprubart

See IMVT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IMVT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.